GHP Healthcare & Pharma Awards 2023 In the Clinical Study, conducted at the Ontario Brain Institute, it was only CQ-001 that demonstrated the statistically significant Clinical Dose and efficacy Study results described above. These results set the stage for substantially smaller dosages of CBD being capable of generating desired results, provided it is combined with essential fatty acids. Another particularly gratifying result is that the drug candidate operates without the negative side effects, and will define a dosage of CQ-001 for a clinical trial. The Phase III, double-blind trial, is now proposed with participation of 60 patients. Furthermore, the regulatory pathways are mapped out and the stage is set to submit applications to Health Canada to go through the process of obtaining approval for a drug as being eligible for Priority Review Status, with a projected approval of timeframe of approximately 18 to 24 months, and the US-FDA to go through the process of obtaining drug eligible for Orphan Drug Status & Priority Review Voucher (PRV), with a projected approval timeframe of approximately 3 years. “The team also found a notable reduction in inflammation in the brain, which could be highly beneficial for other neurological conditions. So, not only did this help innovate the cannabis industry, but the findings can be useful for the universal world of science.” CanaQuest is standing on the brink of a major medical achievement, and not just in the world of medical cannabinoids. It describes it as a transformative, data collection, and growth stage, with a company focus on addressing not just mental health, but potentially other neurological conditions as well. CanaQuest’s future will entail getting sufficient financing in place to conduct the intended clinical studies in 2023 and 2024. It needs these to evaluate the efficacy of Mentanine® on targeted populations, particularly those struggling with transitional issues. It also hopes to conduct a Phase III clinical trial regarding the effects on rare neurological conditions that fall under the umbrella banner of Epilepsy, in 2024. The company is delighted to share that it has recently signed a Master Service Agreement with Neeka Health, which hopefully will allow it to progress its studies into the efficacy of Mentanine® Neeka conducted extensive due diligence on over 90 companies in the cannabinoid research space, before choosing to accept CanaQuest alone. Dr. Hunter Land, the CSO of Neeka, co-led the clinical development of Epidiolex® (FDA-approved prescription CBD) for GW Pharma. He will be leading all the studies for Neeka and CanaQuest. Future goals for CanaQuest involve continuing to build its team and helping to educate people in need. Ultimately, the company is set on improving the quality of life for as many individuals as it can. It has one further note of great importance to impart, which is to explain to potential customers that individual responses to medications can vary, and of course this includes the effects of Mentanine®. The impact may differ from person to person based on factors such as their unique physiology, metabolism, and overall health. It wants to make it clear that as with any formulated product, it’s most important to consult with a medical professional before starting any new medication or supplement. They can provide personalized guidance and dosage recommendations based on your own specific needs and circumstances. The professional way that CanaQuest conducts itself, and the groundbreaking results it is achieving, with its incredible research, are very much respected. It is no wonder it has been awarded the title Best Global Medical Cannabinoid Development Company 2023, in the Healthcare and Pharmaceutical Awards. Unreserved congratulations go out to it, who we are sure will only continue onwards and upwards with its outstanding medical developments. Company: CanaQuest Medical Corp Web Address: www.canaquest.com & www.canaqueststore.com Contact Name: Paul Ramsay CEO [email protected]
RkJQdWJsaXNoZXIy MTUyMDQwMA==